Zydus Lifesciences shares jump 2% to hit 52-week high as US FDA concludes inspection at New Jersey office

According to a regulatory filing, the company said the US FDA conducted an on-site inspection of the company's pharmacovigilance and post-marketing surveillance system at its New Jersey office.

The filing added that the inspection, which was conducted from September 22 to September 25, 2026, concluded with nil observations.

Zydus Lifesciences Q1 results

Zydus Lifesciences reported a 35.93% year-on-year (YoY) fall in its consolidated net profit to ₹939.8 crore in the April-June quarter of the 2026-27 financial year (Q1 FY27), compared with ₹1,466.8 crore in the same period last year.

Its revenue from operations jumped 20.74% YoY to ₹8,123.1 crore during the quarter under review, as against ₹6,728.6 crore in the first quarter of the 2025-26 fiscal year (Q1 FY26).

The pharma major’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) declined 7.6% YoY to ₹1,929.4 crore in the June quarter of FY27, as against ₹2,088.5 crore in the year-ago period.

Its EBITDA margin contracted by 770 basis points (bps) YoY to 24.1% for the reporting quarter, in contrast to 31.8% in Q1 FY26.

Zydus Lifesciences share performance

At around 11:52 AM, the stock stood at ₹1,222.70 per equity share, marking a 1.56% increase.

The scrip has climbed more than 5% in the past week and 3% over the month. On a year-to-date (YTD) basis, it has surged 34%. The shares touched a year’s low of ₹835.50 per unit on April 2, 2026.

Zydus Lifesciences has a total market capitalisation of ₹1.22 lakh crore as of September 28, 2026, according to data on the NSE.